Brokerages Set Korro Bio, Inc. (NASDAQ:KRRO) PT at $142.17

Shares of Korro Bio, Inc. (NASDAQ:KRRO) have earned an average recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $142.17.

KRRO has been the subject of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $115.00 price target on shares of Korro Bio in a research note on Friday, November 22nd. Raymond James assumed coverage on Korro Bio in a research report on Monday, October 21st. They set a “strong-buy” rating and a $153.00 price target on the stock. Finally, Royal Bank of Canada boosted their price objective on Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, October 21st.

Insider Buying and Selling at Korro Bio

In other Korro Bio news, CFO Vineet Agarwal sold 800 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Brown Brothers Harriman & Co. purchased a new position in shares of Korro Bio in the 2nd quarter valued at approximately $28,000. Quest Partners LLC lifted its holdings in shares of Korro Bio by 172.1% during the third quarter. Quest Partners LLC now owns 1,777 shares of the company’s stock worth $59,000 after purchasing an additional 1,124 shares during the period. MetLife Investment Management LLC grew its position in Korro Bio by 129.0% in the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company’s stock valued at $122,000 after buying an additional 2,050 shares during the last quarter. Vestcor Inc acquired a new position in Korro Bio in the 3rd quarter valued at $100,000. Finally, Lynx1 Capital Management LP purchased a new position in Korro Bio during the 2nd quarter worth $129,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Trading Down 9.7 %

KRRO stock opened at $43.96 on Tuesday. Korro Bio has a 52 week low of $30.00 and a 52 week high of $98.00. The firm has a 50 day moving average of $54.28 and a 200 day moving average of $46.20.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, topping the consensus estimate of ($2.55) by $0.29. As a group, analysts predict that Korro Bio will post -9.63 EPS for the current fiscal year.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).